AR118696A1 - Administración mejorada de vectores de tratamiento génico a células retinianas mediante el uso de una enzima glicósido hidrolasa - Google Patents
Administración mejorada de vectores de tratamiento génico a células retinianas mediante el uso de una enzima glicósido hidrolasaInfo
- Publication number
- AR118696A1 AR118696A1 ARP200101063A ARP200101063A AR118696A1 AR 118696 A1 AR118696 A1 AR 118696A1 AR P200101063 A ARP200101063 A AR P200101063A AR P200101063 A ARP200101063 A AR P200101063A AR 118696 A1 AR118696 A1 AR 118696A1
- Authority
- AR
- Argentina
- Prior art keywords
- cells
- retinian
- hydrolase
- gene treatment
- treatment vectors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01129—Endo-alpha-sialidase (3.2.1.129)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a métodos de direccionamiento a tipos específicos de células dentro de la retina mediante el uso de vectores de tratamiento génico optimizados en combinación con una enzima glicósido hidrolasa, tal como neuraminidasa. En particular, la divulgación proporciona vectores de tratamiento génico administrados con una enzima glicósido hidrolasa para dirigirse específicamente a células retinianas y métodos para tratar la discapacidad visual, la degeneración de la retina y trastornos relacionados con la visión.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962849794P | 2019-05-17 | 2019-05-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118696A1 true AR118696A1 (es) | 2021-10-27 |
Family
ID=70482910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200101063A AR118696A1 (es) | 2019-05-17 | 2020-04-15 | Administración mejorada de vectores de tratamiento génico a células retinianas mediante el uso de una enzima glicósido hidrolasa |
Country Status (10)
Country | Link |
---|---|
US (2) | US20220226507A1 (es) |
EP (2) | EP3969059A1 (es) |
JP (2) | JP2022533645A (es) |
KR (1) | KR20220009427A (es) |
CN (1) | CN114126667A (es) |
AR (1) | AR118696A1 (es) |
AU (2) | AU2020278960A1 (es) |
CA (2) | CA3141020A1 (es) |
TW (1) | TW202110486A (es) |
WO (2) | WO2020236352A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114516901B (zh) * | 2022-03-11 | 2023-01-17 | 上海勉亦生物科技有限公司 | 一种神经系统高亲和性的aav载体及其应用 |
CN115323001A (zh) * | 2022-07-28 | 2022-11-11 | 深圳先进技术研究院 | 一种靶向视网膜的基因递送系统及其应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5837484A (en) | 1993-11-09 | 1998-11-17 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
CA2176117C (en) | 1993-11-09 | 2006-01-03 | Terence R. Flotte | Generation of high titers of recombinant aav vectors |
US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
WO1996017947A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
US6143548A (en) | 1995-08-30 | 2000-11-07 | Genzyme Corporation | Chromatographic purification of adeno-associated virus (AAV) |
EP0850313B8 (en) | 1995-09-08 | 2009-07-29 | Genzyme Corporation | Improved aav vectors for gene therapy |
US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
AU723497C (en) | 1996-09-06 | 2001-10-11 | Trustees Of The University Of Pennsylvania, The | Method for recombinant adeno-associated virus-directed gene therapy |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
DK1009808T3 (da) | 1997-09-05 | 2013-01-21 | Genzyme Corp | Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer |
US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
WO2001083692A2 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
GB201403260D0 (en) * | 2014-02-25 | 2014-04-09 | Univ Manchester | Treatment of retinal degeneration using gene therapy |
JP6202701B2 (ja) | 2014-03-21 | 2017-09-27 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及びプログラム |
IL292951B1 (en) * | 2014-05-02 | 2024-06-01 | Genzyme Corp | AAV vectors for gene therapy in the central nervous system and retina |
JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
-
2020
- 2020-04-15 WO PCT/US2020/028352 patent/WO2020236352A1/en unknown
- 2020-04-15 US US17/611,982 patent/US20220226507A1/en active Pending
- 2020-04-15 CA CA3141020A patent/CA3141020A1/en active Pending
- 2020-04-15 AU AU2020278960A patent/AU2020278960A1/en active Pending
- 2020-04-15 AU AU2020278499A patent/AU2020278499A1/en active Pending
- 2020-04-15 CA CA3141017A patent/CA3141017A1/en active Pending
- 2020-04-15 AR ARP200101063A patent/AR118696A1/es unknown
- 2020-04-15 JP JP2021568543A patent/JP2022533645A/ja active Pending
- 2020-04-15 KR KR1020217040926A patent/KR20220009427A/ko unknown
- 2020-04-15 EP EP20723738.9A patent/EP3969059A1/en active Pending
- 2020-04-15 WO PCT/US2020/028207 patent/WO2020236351A1/en unknown
- 2020-04-15 JP JP2021568813A patent/JP2022533983A/ja active Pending
- 2020-04-15 EP EP20727414.3A patent/EP3969060A1/en active Pending
- 2020-04-15 TW TW109112715A patent/TW202110486A/zh unknown
- 2020-04-15 US US17/611,972 patent/US20220233655A1/en active Pending
- 2020-04-15 CN CN202080051735.0A patent/CN114126667A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020236351A1 (en) | 2020-11-26 |
KR20220009427A (ko) | 2022-01-24 |
AU2020278960A1 (en) | 2021-12-23 |
AU2020278499A1 (en) | 2022-01-06 |
JP2022533983A (ja) | 2022-07-27 |
CA3141017A1 (en) | 2020-11-26 |
EP3969060A1 (en) | 2022-03-23 |
TW202110486A (zh) | 2021-03-16 |
US20220233655A1 (en) | 2022-07-28 |
CN114126667A (zh) | 2022-03-01 |
US20220226507A1 (en) | 2022-07-21 |
EP3969059A1 (en) | 2022-03-23 |
JP2022533645A (ja) | 2022-07-25 |
WO2020236352A1 (en) | 2020-11-26 |
CA3141020A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR118696A1 (es) | Administración mejorada de vectores de tratamiento génico a células retinianas mediante el uso de una enzima glicósido hidrolasa | |
WO2016176690A3 (en) | Gene therapy for autosomal dominant diseases | |
AR101961A1 (es) | Composiciones que comprenden células recombinantes de bacillus y otro agente de control biológico | |
AU2017241807A1 (en) | Medium, methods, cells and secreted factors for stem cell culture and therapy | |
BR112016019432A8 (pt) | composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina | |
BR112015005227A2 (pt) | inibidores de glicosilceramida sintase | |
AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
MX2018012695A (es) | Oligomeros antisentido y metodos de uso de los mismos para tratar enfermedades relacionadas con el gen alpha-glucosidasa acido. | |
WO2017143219A3 (en) | Stimulation of therapeutic angiogenesis by t regulatory cells | |
BR112019009116A2 (pt) | métodos e composições para reprogramação celular | |
EP4282472A3 (en) | Methods of treating fabry disease in patients having a mutation in the gla gene | |
MX2022002686A (es) | Cianopirrolidinas sustituidas con actividad como inhibidores de peptidasa 30 especifica de ubiquitina (usp30). | |
GB201202561D0 (en) | Treatment of skin disorders | |
BR112015022907A8 (pt) | formas cristalinas de sal de (2-(2-(4-fluorfenil) tiazol-4-il) propan-2-il) carbamato de (s)-quinuclidin-3-ila e seus usos | |
ZA202203603B (en) | Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast | |
WO2018136669A3 (en) | Therapeutic and neuroprotective peptides | |
MX2022005063A (es) | Tratamiento de enfermedades oculares con antagonistas de receptor de endotelina. | |
PH12017501993A1 (en) | Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy | |
MX2020006944A (es) | Vacuna basada en celulas madre pluripotentes inducidas (ipsc) como un tratamiento profilactico y terapeutico para el cancer. | |
MX2015002570A (es) | Inhibidores de la beta-secretasa. | |
EA201001853A1 (ru) | Фармацевтическая комбинация | |
WO2013052158A3 (en) | Targeted nanovectors and their use for treatment of brain tumors | |
EP3778887A3 (en) | Metabolic therapy for oxidative stress in the brain through targeted neuronal catabolism of n-acetyl-aspartic acid | |
BR112022024794A2 (pt) | Hexahidropirrolo[3,4-b]pirrolo-5(1h)-carbonitrilas com atividade como inibidores de usp30 para uso no tratamento de disfunção mitocondrial, câncer e fibrose | |
BR112022006125A2 (pt) | Composições compreendendo hialuronidase e/ou colagenase e/ou 4-metilumbeliferona (4-mu) e métodos de tratamento usando as mesmas |